Cargando…
Comparative evaluation of galactomannan test with bronchoalveolar lavage and serum for the diagnosis of invasive aspergillosis in patients with hematological malignancies
INTRODUCTION: Invasive pulmonary aspergillosis (IPA) is a major cause of morbidity and mortality in patients with hematological malignancies. In recent years, testing for values of galactomannan (GM) in serum and bronchoalveolar lavage (BAL) fluid has been investigated as a diagnostic test for IPA f...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5607749/ https://www.ncbi.nlm.nih.gov/pubmed/28966482 http://dx.doi.org/10.4103/JLP.JLP_127_16 |
_version_ | 1783265330502565888 |
---|---|
author | Gupta, Ankit Capoor, Malini R. Shende, Trupti Sharma, Bhawna Mohindra, Ritin Suri, Jagdish Chander Gupta, Dipender Kumar |
author_facet | Gupta, Ankit Capoor, Malini R. Shende, Trupti Sharma, Bhawna Mohindra, Ritin Suri, Jagdish Chander Gupta, Dipender Kumar |
author_sort | Gupta, Ankit |
collection | PubMed |
description | INTRODUCTION: Invasive pulmonary aspergillosis (IPA) is a major cause of morbidity and mortality in patients with hematological malignancies. In recent years, testing for values of galactomannan (GM) in serum and bronchoalveolar lavage (BAL) fluid has been investigated as a diagnostic test for IPA for such patients, but global experience and consensus on optical density (OD) cutoffs, especially for BAL galactomannan remains lacking. METHODS: We performed a prospective case–control study to determine an optimal BAL GM OD cutoff for IPA in at-risk patients. Cases were subjects with hematological diagnoses who met established revised definitions for proven or probable IPA established by the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group (EORTC/MSG, 2008), without the use of BAL GM results. Exclusion criteria included the use of piperacillin/tazobactam and use of antifungals that were active against Aspergillus spp. before bronchoscopy. There were two control groups: patients with hematological diagnoses not meeting definitions for proven or probable IPA and patients with nonhematological diagnoses with no evidence of aspergillosis. Following bronchoscopy and BAL, GM testing was performed using the Platelia Aspergillus seroassay in accordance with the manufacturer's instructions. RESULTS: There were 51 cases and 20 controls. Cases had higher BAL fluid GM OD indices (ODIs) (mean: 1.27 and range: 0.4–3.78) compared with controls (mean: 0.26 and range: 0.09–0.35). Receiver operating characteristic analysis demonstrated an optimum ODI cutoff of 1.0, with high specificity (100%) and sensitivity (87.5%) for diagnosing IPA. CONCLUSIONS: Our results support BAL GM testing as a reasonably safe test with higher sensitivity compared to serum GM testing in at-risk patients with hematological diseases. A higher OD cutoff is necessary to avoid overdiagnosis of IPA. |
format | Online Article Text |
id | pubmed-5607749 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Medknow Publications & Media Pvt Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-56077492017-10-01 Comparative evaluation of galactomannan test with bronchoalveolar lavage and serum for the diagnosis of invasive aspergillosis in patients with hematological malignancies Gupta, Ankit Capoor, Malini R. Shende, Trupti Sharma, Bhawna Mohindra, Ritin Suri, Jagdish Chander Gupta, Dipender Kumar J Lab Physicians Original Article INTRODUCTION: Invasive pulmonary aspergillosis (IPA) is a major cause of morbidity and mortality in patients with hematological malignancies. In recent years, testing for values of galactomannan (GM) in serum and bronchoalveolar lavage (BAL) fluid has been investigated as a diagnostic test for IPA for such patients, but global experience and consensus on optical density (OD) cutoffs, especially for BAL galactomannan remains lacking. METHODS: We performed a prospective case–control study to determine an optimal BAL GM OD cutoff for IPA in at-risk patients. Cases were subjects with hematological diagnoses who met established revised definitions for proven or probable IPA established by the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group (EORTC/MSG, 2008), without the use of BAL GM results. Exclusion criteria included the use of piperacillin/tazobactam and use of antifungals that were active against Aspergillus spp. before bronchoscopy. There were two control groups: patients with hematological diagnoses not meeting definitions for proven or probable IPA and patients with nonhematological diagnoses with no evidence of aspergillosis. Following bronchoscopy and BAL, GM testing was performed using the Platelia Aspergillus seroassay in accordance with the manufacturer's instructions. RESULTS: There were 51 cases and 20 controls. Cases had higher BAL fluid GM OD indices (ODIs) (mean: 1.27 and range: 0.4–3.78) compared with controls (mean: 0.26 and range: 0.09–0.35). Receiver operating characteristic analysis demonstrated an optimum ODI cutoff of 1.0, with high specificity (100%) and sensitivity (87.5%) for diagnosing IPA. CONCLUSIONS: Our results support BAL GM testing as a reasonably safe test with higher sensitivity compared to serum GM testing in at-risk patients with hematological diseases. A higher OD cutoff is necessary to avoid overdiagnosis of IPA. Medknow Publications & Media Pvt Ltd 2017 /pmc/articles/PMC5607749/ /pubmed/28966482 http://dx.doi.org/10.4103/JLP.JLP_127_16 Text en Copyright: © 2017 Journal of Laboratory Physicians http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms. |
spellingShingle | Original Article Gupta, Ankit Capoor, Malini R. Shende, Trupti Sharma, Bhawna Mohindra, Ritin Suri, Jagdish Chander Gupta, Dipender Kumar Comparative evaluation of galactomannan test with bronchoalveolar lavage and serum for the diagnosis of invasive aspergillosis in patients with hematological malignancies |
title | Comparative evaluation of galactomannan test with bronchoalveolar lavage and serum for the diagnosis of invasive aspergillosis in patients with hematological malignancies |
title_full | Comparative evaluation of galactomannan test with bronchoalveolar lavage and serum for the diagnosis of invasive aspergillosis in patients with hematological malignancies |
title_fullStr | Comparative evaluation of galactomannan test with bronchoalveolar lavage and serum for the diagnosis of invasive aspergillosis in patients with hematological malignancies |
title_full_unstemmed | Comparative evaluation of galactomannan test with bronchoalveolar lavage and serum for the diagnosis of invasive aspergillosis in patients with hematological malignancies |
title_short | Comparative evaluation of galactomannan test with bronchoalveolar lavage and serum for the diagnosis of invasive aspergillosis in patients with hematological malignancies |
title_sort | comparative evaluation of galactomannan test with bronchoalveolar lavage and serum for the diagnosis of invasive aspergillosis in patients with hematological malignancies |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5607749/ https://www.ncbi.nlm.nih.gov/pubmed/28966482 http://dx.doi.org/10.4103/JLP.JLP_127_16 |
work_keys_str_mv | AT guptaankit comparativeevaluationofgalactomannantestwithbronchoalveolarlavageandserumforthediagnosisofinvasiveaspergillosisinpatientswithhematologicalmalignancies AT capoormalinir comparativeevaluationofgalactomannantestwithbronchoalveolarlavageandserumforthediagnosisofinvasiveaspergillosisinpatientswithhematologicalmalignancies AT shendetrupti comparativeevaluationofgalactomannantestwithbronchoalveolarlavageandserumforthediagnosisofinvasiveaspergillosisinpatientswithhematologicalmalignancies AT sharmabhawna comparativeevaluationofgalactomannantestwithbronchoalveolarlavageandserumforthediagnosisofinvasiveaspergillosisinpatientswithhematologicalmalignancies AT mohindraritin comparativeevaluationofgalactomannantestwithbronchoalveolarlavageandserumforthediagnosisofinvasiveaspergillosisinpatientswithhematologicalmalignancies AT surijagdishchander comparativeevaluationofgalactomannantestwithbronchoalveolarlavageandserumforthediagnosisofinvasiveaspergillosisinpatientswithhematologicalmalignancies AT guptadipenderkumar comparativeevaluationofgalactomannantestwithbronchoalveolarlavageandserumforthediagnosisofinvasiveaspergillosisinpatientswithhematologicalmalignancies |